Lilly’s Foundayo Quickly Gains Ground in the Oral Weight-Loss Market

Lilly's newly launched oral obesity drug, Foundayo, has quickly gained significant market share in the United States. According to Reuters, Foundayo now accounts for over 30% of new patients starting oral weight-loss medications, marking a notable early gain against Novo Nordisk's Wegovy pill. This rapid share capture suggests that the oral GLP-1 market is becoming a more competitive landscape, moving away from Novo's dominance.

The broader U.S. obesity-drug market is projected to exceed $100 billion annually by 2030, with oral treatments potentially accounting for more than one-third of GLP-1 use. Lilly's strategic timing is crucial, as Foundayo was launched in the U.S. in April 2026, making it one of the first new oral weight-loss drugs available. The drug's pricing, starting at $149 per month for self-pay patients and as low as $25 for eligible commercially insured patients, as well as Medicare beneficiaries accessing it through the GLP-1 Bridge program at $50 per month, also contribute to its value proposition.

Lilly's SEC filing highlights that Mounjaro and Zepbound already represent 65% of its revenue in the first half of 2026, emphasizing the importance of the incretin franchise and the potential for Foundayo to broaden Lilly's cardiometabolic revenue base. The strong results of Foundayo, including an average weight reduction of 27.3 pounds (12.4%) among patients who remained on treatment in the ATTAIN-1 trial, suggest that the drug could become a key player in the oral GLP-1 market.